IMMP

Immutep Ltd

Add to Watchlist

Advanced Chart

1.630

-0.01(-0.610%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.660

Open

1.640

VWAP

1.65

Vol

40.48K

Mkt Cap

239.26M

Low

1.630

Amount

66.63K

EV/EBITDA(TTM)

Total Shares

119.98M

224.22M

EV/OCF(TTM)

P/S(TTM)

Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.

2 Analyst Rating

314.11% Upside

Wall Street analysts forecast IMMP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMMP is 6.75 USD with a low forecast of 1.50 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

1 Hold

0 Sell

Moderate Buy

314.11% Upside

Current: 1.630

Low

1.50

Averages

6.75

High

12.00

314.11% Upside

Current: 1.630

Low

1.50

Averages

6.75

High

12.00

Baird

Joel Beatty

Buy

Maintains

$6 → $7

2024-11-15

Reason

Baird

Joel Beatty

Price Target

$6 → $7

2024-11-15

Maintains

Buy

Reason

Baird analyst Joel Beatty raised the firm's price target on Immutep to $7 from $6 and keeps an Outperform rating on the shares. The firm raised its target after the company announced investigator initiated INSIGHT-003 study data today for their lead agent eftilagimod alpha (efti).

See All Ratings

Valuation Metrics

The current forward P/E ratio for Immutep Ltd (IMMP.O) is -6.60, compared to its 5-year average forward P/E of -8.65. For a more detailed relative valuation and DCF analysis to assess Immutep Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-8.65

Current PE

-6.60

Overvalued PE

-6.44

Undervalued PE

-10.87

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-6.17

Current EV/EBITDA

-2.99

Overvalued EV/EBITDA

-3.67

Undervalued EV/EBITDA

-8.68

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

69.02

Current PS

90.00

Overvalued PS

106.29

Undervalued PS

31.75